Raymond James Initiates Coverage On Polaryx Therapeutics with Strong Buy Rating, Announces Price Target of $6
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
Raymond James analyst Tiago Fauth initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Strong Buy rating and announces Price Target of $6.
Raymond James analyst Tiago Fauth initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Strong Buy rating and announces Price Target of $6.